The board of Sanofi India has approved a transaction for the slump sale and transfer of its manufacturing facility at Ankleshwar, Gujarat, to Zentiva and its legal entity in India, Zentiva Private Limited for ₹261.70 crore, subject to customary working capital adjustments. This transaction is subject to shareholders’ approval and the completion of certain conditions as defined under the Business Transfer Agreement. Shareholders will closely monitor further developments.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.